中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/21023
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 29490/55136 (53%)
Visitors : 1511316      Online Users : 659
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    CMUR > College of Medicine > School of Medicine > Proceedings >  Item 310903500/21023
    Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/21023


    Title: THE EFFECTS OF CCY1a-E2 ON WEHI-3 LEUKEMIA MICE IN VIVO
    Authors: 楊家欣;李妙蓉;張瓊云(Chiung-Yun Chang);楊雅茹(Y.J. Yang);王釧如(C.R. Wang);郭盛助;林錦芬*
    Contributors: 醫學院醫學系學士班生化學科
    Date: 2004-04-10
    Issue Date: 2009-09-07 10:40:38 (UTC+8)
    Abstract: Previously we demonstrated that CCY1a-E2 was the most potent derivative of benzyloxybenzaldehyde and it inhibited growth of leukemia cells by induction of cell cycle arrest and apoptosis. In this study, our data showed that CCY1a-E2 also inhibited the proliferation of WEHI-3 leukemia cells in a dose-dependent manner, and the IC50 for 24-hour treatment was 5.0 mM approximately. The purpose of this study was to evaluate the anti-cancer activity of CCY1a-E2 in syngeneic BALB/c mice bearing murine WEHI-3 cells. To confirm the induction of leukemia animal model, BALB/c mice were administrated intravenously at doses of 5x106, 1x106, and 2x105 WEHI-3 cells, respectively. Leukemia were successfully induced 14-28 days later at the dose of 5x106 and 1x106 cells. To assess the acute and chronic toxicity of CCY1a-E2, BALB/c mice were administrated intravenously with 100mg/kg of CCY1a-E2 for 7 days continuously and then sacrificed at the 7th day or the 28th day. No significant toxicity was observed in the CCY1a-E2 treated mice. To evaluate the anti-cancer activity, BALB/c mice were administrated CCY1a-E2 intravenously (100mg/kg) with 1x106 WEHI-3 cells simultaneously, or 7 days after WEHI-3 cells injection. CCY1a-E2 significantly enhanced survival rate, improved the body weight loss, reduced the enlargement of spleen and lymph nodes, and prevented liver metastases in the WEHI-3 bearing mice. Furthermore, analysis of peripheral blood revealed that the number of leukocytes in the CCY1a-E2 treated leukemia mice were significantly lower than that in leukemia mice without treatment. Taken together, CCY1a-E2 has potentially anticancer activity.?
    Relation: The 19th Joint Annual Conference of Biomedical Sciences (2004)
    Appears in Collections:[School of Medicine] Proceedings

    Files in This Item:

    There are no files associated with this item.



    All items in CMUR are protected by copyright, with all rights reserved.

     


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback